This document could contain “forward looking information” within the meaning of applicable Canadian securities legislation. Risks and uncertainties that could cause results of future events to differ materially from current expectations expressed or implied by the forward-looking statements are described in the Company’s financial statement and management’s discussion and analysis as well as other disclosure available under the Company’s profile on www.sedar.com.

At a Glance - Stock Information

Exchange & Trading Symbol TSXV: RX

52 Week High / LowOutstanding Common Shares

Restricted Share Units (28/05/2020)

Fully Diluted (28/05/2020)

Recent Closing Price (28/05/2020)

Options (28/05/2020)

$4.70$8.20 / $3.14

12,808,170

129,125177,512

13,114,807

MAY 2020 Corporate Fact Sheet

BioSyent’s ProductsDomestic Market

Marketed Products Approved

Approved Products (not Marketed)

8

International Market

Brand Sold In

International Markets Signed 10

7

For the seventh consecutive year in 2019, BioSyent was named as one of Canada’s fastest growing companies in the GROWTH 500 rankings with a 5 year revenue growth rate of 176%.

2014 (Base Year) 2019

5 Year Change

13,707,957 (5.73%)

Revenue

# of Marketed Pharma ProductsNet Income Before Tax (NIBT)

Cash

DebtFully Diluted Shares*Diluted EPS

14,540,681

$ 0.31 1.4x$ 0.22

$ 0 -$ 0$ 22.0M 2.8x$ 8.0M

$ 5.9M 1.4x$ 4.3M

8 1.6x5$ 21.4M 1.8x$ 12.2M

*Last equity financing - 2002

Contact Information Investor Relations Address

2476 Argentia Road, Suite 402 Mississauga, Ontario L5N 6M1, Canada

905.206.0013 x323Investors@BioSyent.comwww.BioSyent.com

At a Glance - 5 Years of Growth

About BioSyentListed on the Toronto Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. These products occupy a niche in the market, provide novel technological or therapeutic advantages, are unique due to the complexity of the manufacturing process, and are backed by strong partners who hold intellectual property rights that are defendable. BioSyent is focused on Canada and certain other international regions.

Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the governmental regulatory approval process. Once approved, BioSyent commercializes the product throughout the territories.

BioSyent’s business model is structured to minimize risk and to produce profitable growth. For the three years ending December 31, 2019, the Company had a compound annual revenue growth rate (CAGR) of 2%.

At a Glance - Financial Information

Earnings Per Share (Diluted)

2015 $ 0.262016 $ 0.302017 $ 0.362018 2019 $ 0.31

2015 $ 15,388,196 2016 $ 17,922,270 2017 $ 20,762,755 2018 $ 21,527,028 2019 $ 21,424,324

Net Income After Tax

2015 $ 3,764,889 2016 $ 4,309,505 2017 $ 5,206,277 2018 2019 $ 4,369,295

EBITDA

Market Cap $60,198,399

2015 $ 5,118,792 2016 $ 5,900,080 2017 $ 6,910,977 2018 2019 $ 5,747,706

2

$ 0.39

5,705,386 $ $ 7,405,988

Revenue